Skip to main content

Table 4 Adverse Events that are likely related to antiretroviral therapy at visit +1

From: Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs

  Non-exposed (NE) group Exposed (E) group  
Total number of AEs found NE group: n = 150; E group: n = 75 2 (1.3%) 14 (18.7%) OR 16.8; 95% CI: 3.7-76.9; p  < 0.001
Number of AEs excluding patients with viral load > 50 copies/mL at visit −1 NE group: n = 141; E group: n = 62 2 (1.4%) 11 (17.7%) OR 14.9; 95% CI: 3.2-70.0; p  < 0.001
Number of AEs excluding patients with viral load > 50 copies/mL at baseline visit NE group: n = 136; E group: n = 64 2 (1.5%) 13 (20.3%) OR 17.0; 95% CI: 3.7-78.3; p  < 0.001
Number of AEs excluding patients who recently started treatment with FDCs NE group: n = 132; E group: n = 63 1 (0.8%) 11 (17.5%) OR 27.1; 95% CI: 3.4-215.8; p  < 0.001
Number of AEs excluding patients who recently started treatment with efavirenz NE group: n = 84; E group: n = 50 2 (2.4%) 12 (24.0%) OR 13.5; 95% CI: 2.9-63.5; p  < 0.001
  1. *AEs: adverse events; NE: non-exposed; E: exposed: FDCs: fixed-dose antiretroviral combinations; OR: odds ratio; 95%CI: confidence intervals at the 95% level.